Thrilled to share our new paper in Science! 🎉 We uncover how dietary fat–driven ceramide synthesis activates YAP-dependent regenerative programs to promote colorectal cancer metastasis, independently of primary tumor growth.congrats @SwagataGoswam16 doi.org/10.1126/science.adw8…

Looking forward to our session on "Systems oncology" @CellPressEvents Hallmarks of cancer, with speakers @leeat_keren, Zemin Zhang @CQMU1956, & @TiroshLab. Register today and secure your place: hubs.li/Q04xN7Vx0 #CSHallmarks2026

Pulling out all the stops vs pancreatic cancer. The recent FDA-approved, celebrated drug daraxonrasib, increased median survival by 6.5 months @RevMedicines That's a positive step but clearly not enough. This new @Cancer_Cell paper lays out a path for more. cell.com/cancer-cell/fulltex…

EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery dlvr.it/TVWFDk

We're excited to hear from invited speakers @michelle_monje, Frank Winkler (@HeidelbergU), Timonthy Wang (@ColumbiaCancer) & @moranamit2 in our session on #CancerNeuroscience @CellPressEvents #CSHallmarks2026, Nov 1–3, Sitges, Spain Check out the program: hubs.li/Q04xdplK0

CDK4/6 inhibitors arrest the cell cycle by activating Rb. But the authors provide compelling evidence that the story does not end there. A new Nature study shows that hypophosphorylated Rb unexpectedly enhances ER-mediated transcription. Rb relocates to enhancer regions and reactivates proliferative ER-target genes, including CCND1. So, paradoxically, CDK4/6 inhibition leads to: E2F ↓ → proliferation ↓ but at the same time Rb → ER transcription ↑ → proliferative counter-response ↑ Endocrine therapy shuts down this second pathway. This finding reveals a new mechanism that may help explain the strong biological rationale for combining CDK4/6 inhibition with endocrine therapy, while also pointing to a potential mechanism of resistance. nature.com/articles/s41586-0…

⏰Early bird registration for Hallmarks of cancer closes today! Join us in Sitges, Spain for inspiring science, lively discussions and the breathtaking beauty of the Mediterranean! Register now: hubs.li/Q04v9fjY0 @CellPressEvents #CSHallmarks2026

Our paper is out in @Cancer_Cell! We started this project almost 5 years ago with the idea that to understand why some cancer patients respond to immunotherapy and others do not, we may need to look beyond the tumor before treatment. Immunotherapy is not just a test of a pre-existing state; it is a perturbation. It changes the tumor immune microenvironment. So the question became: can the direction of that change explain response? authors.elsevier.com/a/1niWC…

New paper from @BiffiGiulia in @NatureCellBio comparing fibroblast diversity and epithelial–stromal interactions between #pancreatitis and #PancreaticCancer using a plethora of sample types across species. Congratulations Giulia! nature.com/articles/s41556-0…

#RareCancers face massive bottlenecks: limited patient material, few models, and slow screening pipelines. In our new Forum article in @TrendsCancer, we propose a "Zebrafish-First Triage Strategy" to rapidly model, test, and prioritize targets. cell.com/trends/cancer/fullt…

Hear Timothy Wang @columbiacancer discuss how nerve-cancer connections orchestrate the tumor microenvironment in gastrointestinal tumors @CellPressEvents #CSHallmarks2026 Early bird registration closes September 4! hubs.ly/Q04v9dbJ0

Final version of @NeehaZaidi paper on Mutant KRAS Vaccine for #PancreaticCancer interception in high risk cohorts out in @CD_AACR. aacrjournals.org/cancerdisco… Notable data is detection of KRAS antigen targeted T cells 1 year post vaccine - annual boosters as a prevention strategy?

Pancreatic cancer is notoriously hard to treat, but we are making progress. Recent @theNCI -funded work that sheds light on mechanisms behind #daraxonrasib resistance and could help clinicians choose treatment combos that outsmart pancreatic tumors. go.nih.gov/AcvCu95

📢Call for late-breaking abstracts! Have new or groundbreaking findings to share? #CSHallmarks26 is now accepting late-breaking abstract submissions. Submit by October 16 and help shape the future of cancer research. 👉hubs.li/Q04vpWM40 @CellPressEvents

Invited speaker Itay Tirosh @TiroshLab @WeizmannScience will discuss cancer cell states and their spatial organization @CellPressEvents #CSHallmarks2026 in Sitges, Spain, Nov 1–3, 2026. Register here for a chance to join him: hubs.li/Q04rDLSN0

Now online! Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer dlvr.it/TTt4xv

Thrilled to share our latest work is out today in @Nature ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer. nature.com/articles/s41586-0…

Our paper is out today in Cancer Discovery: Systematic Targeting of Protein Complexes with Molecular COUPLrs. What if, instead of simply inhibiting proteins, we could design small molecules that permanently staple two proteins together aacrjournals.org/cancerdisco…

3 papers in @Nature today reflecting large scale efforts at mapping dependencies and multimodal molecular profiling data from a large panel of patient-derived 3D cancer models. This is DepMap on steroids! nature.com/articles/s41586-0… nature.com/articles/s41586-0… nature.com/articles/s41586-0…

🚨Abstract deadline today! This is your last chance to have your work considered for a short talk @CellPressEvents #CSHallmarks2026 Join us in Sitges for inspiring science, lively discussions and the breathtaking beauty of the Mediterranean! Submit now: hubs.li/Q04pRKdd0